Experts say the anti-inflammatory ingredient can help with muscle recovery and manage chronic pain, among other benefits.

While people swear by their favorite home remedies, most—including the three described above—remain unproved. Every now and then, however, a piece of folklore is scientifically validated. Sometimes ...

You’ve likely heard of their healing powers. A new book provides a detailed look at herbal remedies for treating common ailments—from easing cramps to uplifting moods. A mandala offering made from ...

Most of the supplements that support lung health exert their benefit through decreasing inflammation. However, more human clinical studies are needed to evaluate their safety. Supplements that may ...

In an age where respiratory health has gained unprecedented attention, innovative solutions like Breathe Drops for Lungs are shaping how individuals approach breathing difficulties. This product ...

This simple diagram shows a healthy lung (left) and one with chronic obstructive pulmonary disease, or COPD. (AdobeStock) Buy Photo The Gazette offers audio versions of articles using Instaread. Some ...

Decongestants and antihistamines can help reduce mucus and improve sinus drainage. Most sinus infections get better without needing antibiotics. Chronic sinus problems may require surgery to open ...

Please provide your email address to receive an email when new articles are posted on . Patients receiving roflumilast vs. azithromycin had a reduced risk for COPD exacerbations at 1 year but an ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...

In rats with COPD, TP-TR, a traditional Chinese medicine herbal pair, improved lung function and reduced inflammation TP-TR treatment altered the gut microbiome composition, increasing beneficial ...

“This new COPD diagnostic schema, which includes chest imaging, respiratory symptoms and spirometry, identified additional individuals at risk of poor respiratory outcomes,” said Bhatt, a professor in ...

Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...